TRAF3 and lymphoma: Notably, 20–30% of these lymphomas had inhibitory mutations in TRAF3. TRAF3 is a negative regulator of the non-canonical NF-kB signaling pathway, and when inactivated leads to constitutive processing of p100 to p52 for translocation into the nucleus with its partner, RelB (46, 47).